Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) is a clinical-stage oncology company developing small-molecule therapies for cancers driven by genetically defined mutations. Its MasterKey therapies target families of oncogenic mutations, and its proprietary Mutation-Allostery-Pharmacology (MAP) drug discovery engine… From the company’s description.
In fiscal 2025, Black Diamond Therapeutics, Inc. reported revenue of $70.00M and net income of $22.37M. Its operating margin was 17.9%, and operations generated $29.61M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Black Diamond Therapeutics, Inc. does
In the company’s own words
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) is a clinical-stage oncology company developing small-molecule therapies for cancers driven by genetically defined mutations. Its MasterKey therapies target families of oncogenic mutations, and its proprietary Mutation-Allostery-Pharmacology (MAP) drug discovery engine supports their discovery. The lead candidate, silevertinib, is an oral, brain-penetrant EGFR inhibitor being studied in Phase 2 trials for EGFR-mutant non-small cell lung cancer (NSCLC), with development planned for EGFR-altered glioblastoma. The pipeline also includes BDTX-4933, a RAF inhibitor licensed globally to Servier, which is responsible for its development and commercialization, and BDTX-4876, an FGFR2/3 inhibitor for which the company is exploring partnerships. Black Diamond focuses on research and development and does not report operating segments. Founded in 2014, it began building the MAP platform with Versant Ventures in 2017. Its website is www.blackdiamondtherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1701541
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Black Diamond Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Black Diamond Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Black Diamond Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Black Diamond Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Black Diamond Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”